ストックスクリーナーアプリを入手
1.35
3.85%
0.05
アフターアワーズ：
1.34
-0.01
-0.74%
Acurx Pharmaceuticals Inc (ACXP) 最新ニュース
MicroStrategy Now Has Copycats Buying Bitcoin as Prices Near $100,000 - Barron's
Nasdaq-Listed Acurx Invests $1M in Bitcoin—What’s Behind the Move? - Watcher Guru
Acurx Pharmaceuticals Allocates $1 Million to Bitcoin as Reserve Asset, Shares Slide 26% - Binance
Acurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin Investment - MarketWatch
ACXP stock touches 52-week low at $1.5 amid market challenges - Investing.com UK
Acurx Pharmaceuticals adopts Bitcoin as a reserve asset - TU News
Acurx Pharmaceuticals allocates $1M for Bitcoin reserve - Investing.com
Acurx Pharmaceuticals allocates $1M for Bitcoin reserve By Investing.com - Investing.com UK
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset - Vietnam Investment Review
ACXPAcurx Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Acurx Pharma Advances CDI Drug to Phase 3 Trials After Promising Clinical Data | ACXP Stock News - StockTitan
HC Wainwright Has Bullish Estimate for ACXP FY2024 Earnings - Defense World
Acurx Pharmaceuticals Reports Q3 2024 Financial Results and Business Update - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Decline in Short Interest - Defense World
Acurx Pharmaceuticals’ (ACXP) Buy Rating Reiterated at HC Wainwright - Defense World
Keith Meister's Corvex opens fresh stakes in Dollar Tree, APD, exits CAE: top Q3 trades - MSN
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss - MSN
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2024 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals Reports Promising Q3 2024 Results - TipRanks
Acurx Pharma Q3: New Patent Win & Trial Progress Despite Cash Decline to $5.8M | ACXP Stock News - StockTitan
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acurx Pharmaceuticals (ACXP) Set to Announce Quarterly Earnings on Wednesday - Defense World
New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the... - Markets Insider
New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKUR’s "Hack of the Week" - AccessWire
New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPTH) - Quantisnow
AccreditedEvents.com Unveils Premier Lineup for November and December Investor Events - Big News Network
Acurx reports positive Phase 2 results for CDI treatment ibezapolstat - Investing.com India
Acurx reports positive Phase 2 results for CDI treatment ibezapolstat By Investing.com - Investing.com South Africa
Acurx Ready To Expand Pipeline With Anthrax Treatment (NASDAQ:ACXP) - Seeking Alpha
Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference - StockTitan
Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement - StockTitan
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 - StockTitan
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support - Bluefield Daily Telegraph
New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 6:30 PM EST - AccessWire
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST - The Hastings Tribune
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Growth in Short Interest - Defense World
Acurx reports ibezapolstat's positive microbiome effects and Anthrax activity - Investing.com
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues - StockTitan
Acurx Announces Anthrax Susceptibility to ACX-375 Analogues - Global Biodefense
Acurx readies ibezapolstat for Phase 3 CDI trials By Investing.com - Investing.com Australia
Acurx readies ibezapolstat for Phase 3 CDI trials - Investing.com
Acurx announces results of Phase 2 ibezapolstat trial in C. difficile Infection - TipRanks
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium - StockTitan
Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Down 7% - Defense World
ACM Research, Inc. (ACMR) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
ACM Research Inc (ACMR) stock: A year of ups and downs - US Post News
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):